title: Transurethral collagen injections for male intrinsic sphincter deficiency: the University of Texas-Houston experience.
abstract: OBJECTIVE
  Injectable agents are used to increase urethral coaptation for the treatment of intrinsic sphincter deficiency. We evaluated the long-term results and complications of transurethral collagen injections in males.
  
  
  METHODS
  We reviewed the charts of 322 men (mean age 67.2 years, range 40 to 91) with intrinsic sphincter deficiency after therapy for prostate carcinoma (307) or benign prostatic hyperplasia (15) who received transurethral collagen injections. The analysis included types and combinations of treatment for prostate cancer or benign prostatic hyperplasia, pre-procedure voiding symptoms, total collagen received, maximal percentage improvement and durability of effect.
  
  
  RESULTS
  The mean length of followup was 40.1 (+/-13.2) months. Overall, the mean number of injections was 4.37 (+/-2.09). Mean percent improvement after a series of injections was 44.59 (+/-38.26). Mean pad use before and after injection was statistically different (5.15 vs 2.98, p=0.0001). Mean duration of response was 6.3 (+/-8.14) months. In those who achieved complete continence (17%), the mean duration of response was 11.1 (+/-8.87) months. Within this group the mean number of injections and ml of collagen injected were 3.83 and 29.27, respectively. Five patients (1.5%) complained of a quantitative increase in leakage after their series of collagen injections.
  
  
  CONCLUSIONS
  Transurethral collagen injections are a good option for short-term therapy in men with post-prostatectomy incontinence. The mean number of injections to achieve a plateau is 3 to 4, regardless of initial severity of incontinence. Those in the radical prostatectomy only treatment group are statistically more likely to achieve continence than all other treatment groups.
authors.affiliation: Division of Urology, University of Texas Houston Health Science Center at Houston, 77030, USA. Ouida.L.Westney@uth.tmc.edu
authors.forename: O Lenaine
authors.initials: OL
authors.lastname: Westney
authors.forename: Richard
authors.initials: R
authors.lastname: Bevan-Thomas
authors.forename: J Lynn
authors.initials: JL
authors.lastname: Palmer
authors.forename: R Duane
authors.initials: RD
authors.lastname: Cespedes
authors.forename: Edward J
authors.initials: EJ
authors.lastname: McGuire
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003094:Collagen / Q000008:administration & dosage*; D005500:Follow-Up Studies; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D009123:Muscle Hypotonia / Q000628:therapy*; D011183:Postoperative Complications / Q000628:therapy*; D011468:Prostatectomy; D011470:Prostatic Hyperplasia / Q000601:surgery*; D011471:Prostatic Neoplasms / Q000601:surgery*; D012189:Retrospective Studies; D016896:Treatment Outcome; D014549:Urinary Incontinence / Q000628:therapy*
chemical_list: D003094:Collagen